Endometrial cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 5
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,290 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Terminated

  Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

  NCT05833321· Centre Hospitalier Metropole Savoie· Updated 8 Oct 2026

  “recruitement failure”Registry text, quoted unchanged. Source

• Suspended

  Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

  NCT04683653· University of Chicago· Updated 10 Sept 2026

  “Enrollment Goal Met”Registry text, quoted unchanged. Source

• Terminated

  Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

  NCT05827614· Boundless Bio, Inc.· Updated 19 Aug 2026

  “Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.”Registry text, quoted unchanged. Source

• Terminated

  A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

  NCT05572684· NextCure, Inc.· Updated 13 Aug 2026

  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”Registry text, quoted unchanged. Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Genmab· Updated 23 Jul 2026

  “The Sponsor has made a strategic decision to stop the development of GEN1047.”Registry text, quoted unchanged. Source

• Terminated

  NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

  NCT05714553· NuCana plc· Updated 23 Jul 2026

  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”Registry text, quoted unchanged. Source

• Terminated

  The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

  NCT04527900· University of Maryland, Baltimore· Updated 8 Jul 2026

  “SOC changed and low enrollment”Registry text, quoted unchanged. Source

• Terminated

  Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

  NCT05316467· Xiaojun Chen· Updated 4 Jun 2026

  “no enough enrolled patients”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Source

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Merck Sharp & Dohme LLC· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• Developing a Gynecologic Cancer Health Promotion Community Engagement Program

  NCT07910162· Abramson Cancer Center at Penn Medicine· Source

• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  NCT05112601· National Cancer Institute (NCI)· Source

• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· National Cancer Institute (NCI)· Source

• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· AstraZeneca· Source

• Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

  NCT06253494· National Cancer Institute (NCI)· Source

• Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers

  NCT07815873· European Institute of Oncology· Source

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), Sept 2026

• Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs.

  Medicine (Baltimore), Sept 2026

• Integration of Spatial Transcriptomics and Mendelian Randomization Identifies Candidate Molecular Regulators of Endometrial Cancer Progression.

  Cells, Aug 2026

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, Jul 2026

• Type 2 diabetes mellitus and cancer: A systematic review and meta-analysis of Mendelian randomization studies.

  Front Endocrinol (Lausanne), Apr 2026

• Causal associations between Sjögren's syndrome and subtypes of endometrial cancer.

  BMC Immunol, Apr 2026

• Female Reproductive Traits and Late-Life Hormone-Sensitive Cancer Risk: A Mendelian Randomization Study.

  Cancer Prev Res (Phila), Apr 2026

• Causal relationship between renin-angiotensin system inhibitors and cancer: a two-sample, two-step Mendelian randomization study.

  Chin Clin Oncol, Feb 2026

• Causal relationship between diet and common female diseases: a comprehensive Mendelian randomization study.

  BMC Womens Health, Dec 2025

• Causal Relationships Between Pregnancy, Menstrual History, and Endometrial Cancer With Mediating Effects of Metabolism-Related Traits.

  Hum Mutat, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.